logo
Deadly Massachusetts fire highlights the minimal regulations that govern assisted-living facilities

Deadly Massachusetts fire highlights the minimal regulations that govern assisted-living facilities

The Massachusetts assisted-living facility where a fatal fire killed nine people was caring for dozens of aging residents reliant on wheelchairs and oxygen tanks, but it lacked the safety measures and most of the staffing requirements that are commonplace in nursing homes.
As an assisted-living center, Gabriel House in Fall River , about 50 miles (80 kilometers) south of Boston, offered a type of housing for older residents that has expanded nationally in recent decades. But advocates argue that the absence of any federal regulations and spotty state rules mean the sector is largely left to police itself.
'The real issue is that assisted livings operate in an environment like the Wild West,' said Richard Mollot, executive director of the Long Term Care Community Coalition, a nonprofit that advocates for improved care in nursing and assisted-living facilities. 'They can pretty much do what they want with impunity, and that results in a lot of, I would say, mini-catastrophes every day, frankly.'
The fire that tore through the three-story structure late Sunday raised a host of questions about conditions at the dilapidated facility and put the spotlight on the growing number of assisted-living centers in the state and nationwide.
Created in the 1980s, assisted living has been marketed as an option for older adults who need some assistance but not as much help as a nursing home. Advocates argue that regulations for the facilities have not kept up as more locations have opened.
Nursing homes, for example, are governed by federal regulations because they receive Medicare and Medicaid while there are no federal regulations for assisted-living facilities. Nursing homes must have a minimum number of staffers and trained medical professionals such as doctors and nurses, but assisted-living facilities have no such requirements.
'The regulations are minimal,' said Liane Zeitz, an attorney who is also a member of the state Assisted Living Residences Commission, a body created to make recommendations about the sector. She has advocated for more regulations for assisted-living facilities.
The facilities were lightly regulated because initially they were regarded as residential, with lower levels of care and less oversight, she said. But now those facilities are caring for a population 'that is much frailer, and the population is growing.'
Not only are the regulations weaker for assisted-living facilities, but advocates argue that the enforcement of the existing rules is often lax.
Paul Lanzikos, a former Massachusetts secretary of elder affairs and co-founder of the advocacy group Dignity Alliance, described a 'patchwork' of regulations across the country, with different agencies involved depending on the state.
'Some of the states are much more regulated. Some are regulated as a health care entity. Others, as we do here in Massachusetts, are considered a residential housing model,' he said.
U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, has been advocating for increased oversight for years, particularly after the release of reports about health and safety problems in 2018.
'These are serious problems that have been going on for years,' she said at a hearing last year. 'But we hear so much less about what's going in assisted-living facilities than we do in other facilities, like nursing homes.'
At that hearing, Mollot noted that scandals in the nursing home industry pushed Congress to act in the 1970s and 1980s, and that such a reckoning could be coming soon for assisted living. He described two major risks: increasingly sick and vulnerable assisted living residents and financial exploitation by owner investors.
Speaking Wednesday after learning about the Gabriel House fire, Mollot said the problems that plagued that facility are not unique to Massachusetts.
'Unlike nursing homes, assisted living has no federal state requirements, no requirement for staffing, no requirements for staff training, no requirements for safety protocols, no requirements for inspections,' he said. 'That falls to the states, and the states have overall very weak rules.'
___
Associated Press writers Holly Ramer and Matt O'Brien contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Planned Parenthood wins partial victory in legal fight with Trump administration over funding cuts
Planned Parenthood wins partial victory in legal fight with Trump administration over funding cuts

Associated Press

time2 hours ago

  • Associated Press

Planned Parenthood wins partial victory in legal fight with Trump administration over funding cuts

BOSTON (AP) — Planned Parenthood won a partial victory Monday in a legal fight with President Donald Trump's administration over efforts to defund the organization in his signature tax legislation. A provision in that bill would end Medicaid payments to abortion providers for one year. But U.S. District Judge Indira Talwani in Boston granted a preliminary injunction Monday that, for now, blocks the government from cutting Medicaid payments to Planned Parenthood member organizations that either don't provide abortion care or didn't meet a threshold of at least $800,000 in Medicaid reimbursements in a given year. It wasn't immediately clear how many Planned Parenthood organizations and clinics would continue to get Medicaid reimbursement under that decision and how many might not. The lawsuit was filed earlier this month against Health and Human Services Secretary Robert F. Kennedy Jr. by Planned Parenthood Federation of America and its member organizations in Massachusetts and Utah. A Planned Parenthood spokesperson said its lawyers were still examining the order and would release a statement shortly.

Federal judge blocks Trump administration from defunding Planned Parenthood
Federal judge blocks Trump administration from defunding Planned Parenthood

Fox News

time2 hours ago

  • Fox News

Federal judge blocks Trump administration from defunding Planned Parenthood

A judge on Monday temporarily blocked the Trump administration from stripping Medicaid funds from Planned Parenthood after Congress and President Donald Trump agreed to partially defund the nonprofit through passage of the One Big Beautiful Bill Act. Judge Indira Talwani of the U.S. District Court for the District of Massachusetts said in her order partially granting a preliminary injunction that the bill unconstitutionally punishes Planned Parenthood member organizations that do not provide abortions. The injunction will risk "at most minimal harm—financial or otherwise—to" the Trump administration while the lawsuit proceeds," Talwani, an Obama appointee, wrote. Talwani's order arose from a lawsuit brought by Planned Parenthood, the nation's largest abortion vendor, over the One Big Beautiful Bill Act, a massive budget bill that passed Congress this month with no Democrat support. Trump signed the bill into law on July 4. A provision in the bill stripped Medicaid funding from Planned Parenthood, which the nonprofit said could force it to close about 200 of its 600 facilities and deprive about half of its customers, more than one million people, of services that do not include abortion. Planned Parenthood attorneys noted in court filings that Medicaid does not cover abortion. The attorneys argued that cancer and sexually transmitted infections would go undetected, especially for low-income people, and that more unplanned pregnancies would occur because of a lack of contraception access. They said the consequences of losing Medicaid funding "will be grave." Department of Justice (DOJ) attorneys had previously argued in court filings that the purpose of the budget provision was to stop "federal subsidies for Big Abortion" by freezing federal funds for certain Medicaid recipients who provide abortions. Weakening Planned Parenthood has been one of the pro-life movement's leading priorities since the Supreme Court overturned Roe v. Wade. Talwani granted a temporary restraining order two weeks ago in favor of Planned Parenthood. The judge initially offered no explanation for her decision, a move that led to widespread backlash among Republicans who described it as judicial overreach. Days later, Talwani offered more context in a subsequent order. The preliminary injunction will leave in place the pause on defunding Planned Parenthood indefinitely, but the Trump administration is likely to appeal the order to the U.S. Court of Appeals for the First Circuit. DOJ attorneys had previously argued to the court that blocking a measure that was passed by Congress and signed by the president was an extraordinary move and unjustified. "Beyond the futility of the claims on the merits, Planned Parenthood fails to demonstrate imminent irreparable harm to justify an injunction, asserting only classically reparable economic injury and irrelevant potential harm to patients, who are third parties not before this Court," DOJ attorneys wrote.

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

Yahoo

time3 hours ago

  • Yahoo

Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.

CAMBRIDGE, Mass., July 21, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeutics notified the U.S. Food and Drug Administration (FDA) of its decision to voluntarily and temporarily pause all shipments of ELEVIDYS (delandistrogene moxeparvovec) for Duchenne muscular dystrophy in the United States, effective close of business Tuesday, July 22, 2025. This proactive step will allow Sarepta the necessary time to respond to any requests for information and allow Sarepta and FDA to complete the ELEVIDYS safety labeling supplement process. The Company looks forward to a collaborative, science-driven review process and dialogue with the FDA. "As a patient-centric organization, the decision to voluntarily and temporarily pause shipments of ELEVIDYS was a painful one, as individuals with Duchenne are losing muscle daily and in need of disease-modifying options," said Doug Ingram, chief executive officer, Sarepta. "It is important for the patients we serve that Sarepta maintains a productive and positive working relationship with FDA, and it became obvious that maintaining that productive working relationship required this temporary suspension while we address any questions that FDA may have and complete the ELEVIDYS label supplement process." Sarepta remains committed to transparency and patient safety and will continue to provide timely updates to patients, families, healthcare providers, and the broader Duchenne community as additional information becomes available. About ELEVIDYS (delandistrogene moxeparvovec-rokl)ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS:Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains "forward-looking statements." Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, ELEVIDYS, ongoing interactions with FDA related to ELEVIDYS, and our decision to voluntarily and temporarily pause shipments of ELEVIDYS in the United States. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; different methodologies, assumptions and applications we use to assess particular safety or efficacy parameters may yield different statistical results, and even if we believe the data collected from clinical trials are positive, the results of future research may not be consistent with past positive results, or may fail to meet regulatory approval requirements for the safety and efficacy of product candidates; we may not be able to comply with all FDA requests in a timely manner or at all; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading "Risk Factors" in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. View source version on Contacts Investor Contact: Ian Estepan617-274-4052iestepan@ Media Contacts: Tracy Sorrentino617-301-8566tsorrentino@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store